Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Grupo ISA
Oegstgeest, South Holland, Netherlands
- Ownership
- Private
- Employees
- ~36
- Development stage
- Other
01
Overview
ISA Pharmaceuticals is a clinical-stage immunotherapy company using its Synthetic Long Peptide (SLP) and AMPLIVANT platforms to develop therapeutic vaccines against cancer and persistent viral infections, with multiple SLP compounds demonstrating safety, tolerability, and proof-of-concept efficacy in trials up to Phase 2, including ISA101b in HPV16-positive cancers and ISA104 in Phase 1 for chronic hepatitis B.[1][5][8][2][10][3]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineTherapeutic vaccineProphylactic vaccineSynthetic peptide vaccinePeptidesBiologic
- Industry
- Biotech
02
Partnerships
Regeneron (collaboration on ISA101b in HPV16 induced cancers, including combination with cemiplimab)[2][9]Erasmus MC (clinical trial HEB-PEP for ISA104 in chronic hepatitis B)[8][2]MD Anderson Cancer Center (Phase 1b/2 trial of ISA103 in uveal melanoma in combination with checkpoint inhibitors, via Cancer Focus Fund collaboration)[3][10]Cancer Focus Fund (investment and clinical collaboration for ISA103)[3]
Beyond the preview
Go deeper on Grupo ISA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Grupo ISA.